Gossamer Bio
GOSS
100 hedge funds and large institutions have $173M invested in Gossamer Bio in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 31 reducing their positions, and 10 closing their positions.
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
36% more call options, than puts
Call options by funds: $785K | Put options by funds: $579K
6% more funds holding
Funds holding: 94 → 100 (+6)
5% more capital invested
Capital invested by funds: $165M → $173M (+$7.91M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.53% less ownership
Funds ownership: 80.83% → 77.3% (-3.5%)
19% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Monaco Asset Management
Monaco
|
+$1.08M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$904K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$426K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$342K |
| 5 |
Two Sigma Investments
New York
|
+$309K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$12M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.94M |
| 3 |
Millennium Management
New York
|
-$2.37M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.63M |
| 5 |
Goldman Sachs
New York
|
-$1.33M |
GOSS Hedge Fund Activity: Q3 2024 in Review
100 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q3 2024, worth a combined $173M — up 4.8% from $165M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GOSS positions and 10 closed out — a net gain of 6 holders — while 25 added to existing stakes and 31 trimmed.
The largest buyer was Monaco Asset Management, adding an estimated $1.08M. The largest seller was Artal Group, exiting entirely with an estimated $12M sold.
- 100 institutional investors held Gossamer Bio (GOSS) as of Q3 2024, up from 94 in Q2 2024.
- Funds reported $173M of Gossamer Bio stock for Q3 2024, up 4.8% quarter-over-quarter.
- 16 funds opened new Gossamer Bio positions in Q3 2024 and 10 closed out, a net change of +6 holders.
- The largest Gossamer Bio buyer in Q3 2024 was Monaco Asset Management, an estimated $1.08M added.
- The largest Gossamer Bio seller in Q3 2024 was Artal Group, an estimated $12M sold.
Based on aggregated 13F filings for Q3 2024.